射波刀治疗小细胞肺癌脑转移的疗效分析

目的:探讨射波刀立体定向放射外科（SRS）治疗小细胞肺癌（SCLC）脑转移（BM）的有效性及安全性。方法:回顾性分析2006年7月-2015年12月期间SRS 治疗的28例SCLC脑转移的患者资料，其中包括全脑放疗（WBRT）与SRS联合治疗 13例，SRS挽救性治疗15例。分析总生存时间（OS）、颅内局部控制率（LC）及颅内无远处转移生存（DMFS）情况。结果:中位随访时间为13个月，中位生存期为12个月，1年、2年的OS分别为50.0%、22.2%；1年、2年的LC分别为85.4%、76.8%； 6个月、1年、2年的DMFS为73.9%、66.1%、38.2%。治疗后1.5月内，1~2级急性毒副反应发生率为10%，未见3级及3级以上急性毒副反应。结论:SRS治疗SCLC脑转移患者可取得较好的生存率，并且不良反应少，是安全有效的方法。

The effectiveness of CyberKnife for brain metastases from small cell lung cancer

Objective: To evaluate the efficacy and safety of CyberKnife stereotactic radiosurgery(SRS) in the treatment of patients with brain metastases (BM) from small cell lung cancer(SCLC). Methods: A group of 28 patients with brain metastases from small cell lung cancer treated with CyberKnife SRS from July 2006 to December 2015 were retrospectively studied. There were 13 cases of whole brain radiotherapy(WBRT) combined with stereotactic radiosurgery and 15 cases of salvage stereotactic radiosurgery therapy. Overall survival (OS), Local contral(LC) and Distant metastases free survival(DMFS) were analyzed to assess the efficacy. Results: In a median follow-up of 13 months, the median overall survival was 12 months, 1-and 2-year overall survivals were 50.0% and 22.2%; 1-and 2-year local contral were 85.4% and 76.8%, respectively; the median time for distant metastases was 6 months, 1-and 2-year distant metastases free survivals were 66.1% and 38.2%. Within 1.5 months after treatment, the incidence of acute toxic and side effects of grade 1-2 was 10%, and no acute side effects of grade 3 or higher were observed. Conclusion: CyberKnife SRS can achieve higher survival rate and less adverse reactions in the treatment of SCLC brain metastasis, and it may be a safe and effective method.